Background: Recent studies reported ADHD-like symptoms and cognitive deficits in pervasive developmental disorder (PDD). Because work in dementia documents improvement in executive function deficits with the acetylcholinesterase inhibitor donepezil, the authors reason that similar benefits could be obtained in PDD. Method: The authors describe eight cases of PDD youth ages 10 to 17 treated with donepezil targeting ADHD-like symptoms associated with PDD. Results: Most participants improve ADHD-like symptomatology. In addition, improvement in communication and socialization is noted. Conclusion: Donepezil may have a role in treating ADHD-like symptoms in children with PDD.
Balducci, C., Nurra, M., Pietropoli, A., Samanin, R., & Carli, M. (2003). Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635. Psychopharmacology, 167(1), 28-36.
2.
Barner, E. L., & Gray, S. L. (1998). Donepezil use in Alzheimer’s disease. Annals of Pharmacotherapy, 32, 70-77.
3.
Bauman, M. L., & Kemper, T. L. (1994). Neurobiology of autism. Baltimore: Johns Hopkins University Press.
4.
Bontempi, B., Whelan, K. T., Risbrough, V. B., Lloyd, G. K., & Menzaghi, F. (2003). Cognitive enhancing properties and tolerability of cholinergic agents in mice: A comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotine acetylcholine receptors. Neuropsychopharmacology, 28(7), 1235-1236.
5.
Buccafusco, J. J., & Terry, A. V. (2004). Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. Journal of Molecular Neuroscience, 24(1), 85-91.
6.
Courchesne, E., Press, G. A., & Yeung-Courchesne, R. (1993). Parietal lobe abnormalities detected with magnetic resonance in patients with autism. American Journal of Roentgenol, 160, 387-393.
7.
Findling, R. L. (1996). Open-label treatment of comorbid depression attentional disorders with coadministration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: A case series. Journal of Child and Adolescent Psychopharmacology, 6, 165-175.
8.
Frazier, J. A., Biederman, J., Bellordre, C. A., Garfield, S. B., Geller, D. A., Coffey, B. J., et al. (2001). Should the diagnosis of Attention-Deficit/Hyperactivity disorder be considered in children with pervasive developmental disorder?Journal of Attention Disorders, 4(4), 203-211.
9.
Gaffney, G. R., Kuperman, S., Tsai, L. Y., & Minchin, S. (1989). Forebrain structure in infantile autism. Journal of the American Academy of Child and Adolescent Psychiatry, 28, 534-537.
10.
George, M. S., Costa, D. C., Kouris, K., Ring, H. A., & Ell, P. J. (1992). Cerebral blood flow abnormalities in adults with infantile autism. Journal of Nervous and Mental Disease, 180, 413-417.
11.
Hardan, A. Y., & Handen, B. L. (2002). A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 12(3), 237-241.
12.
Haznedar, M. M., Buchsbaum, M. S., Metzger, M., Solimando, A., Spiegel-Cohen, J., & Hollander, E. (1997). Anterior cingulate gyrus volume and glucose metabolism in autistic disorder. American Journal of Psychiatry, 154, 1047-1050.
13.
Jones, G., Sahakian, B. J., Levy, R., Warburton, D. M., & Gray, J. A. (1992). Effects of acute subcutaneous nicotine on attention, information, and short tem memory in Alzheimer’s disease. Psychopharmacology, 108, 485-494.
14.
Kemper, T. L., & Bauman, M. L. (1993). The contribution of neuropathologic studies to the understanding of autism. Neurology, 11, 175-187.
15.
Levin, E. (1992). Nicotinic systems and cognitive function. Psychopharmacology, 108, 417-431.
16.
Levin, E., Conners, C. K., Sparrow, E., Hinton, S. C., Erhardt, D., Meck, W. H., et al. (1996). Nicotinic effects on adults with attention deficit hyperactivity disorder. Psychopharmacology, 123, 55-63.
17.
Luine, V. (2002). Chromaproline and chromaperidine, nicotine agonists, and donepezil, cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats. Pharmacology Biochemistry Behavior, 74(1), 213-220.
18.
McCracken, J. T., McGough, J, Bhavik, S., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Risperdone in autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314-321.
19.
Mereu, G., Yoon, K. W., Boi, V., Gessa, G. L., Naes, L., & Westfall, T. C. (1987). Preferential stimulation of ventral tegmental area dopminergic neurons by nicotine. European Journal of Pharmacology, 141, 395-399.
20.
National Institute of Mental Health. (1985). Clinical Global Impression Scale. Psychopharmacology Bulletin, 21(4), 839-844.
21.
Pennington, B. F., & Ozonoff, S. (1996). Executive functions and developmental psychopathology. Journal of Child Psychology and Psychiatry, 37, 51-87.
22.
Perry, E. K., Lee, M. L. W., Martin-Ruiz, C. M., Court, J. A., Volsen, S. G., Merrit, J., et al. (2001). Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. American Journal of Psychiatry, 158, 1058-1066.
23.
Rockwood, K., Black, S. E., Robillard, A., & Lussier, I. (2004). Potential treatment effects of donepezil not detected in Alzheimer’s disease clinical trials: A physician survey. International Journal of Geriatric Psychiatry, 19(10), 954.
24.
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with alzheimer’s disease. Neurology, 50, 136-145.
25.
Rogers, S., & Teaneck, N. (1996). Clinical profile of donepezil. Neurobiology of Aging, 17(Suppl.), 181-186.
26.
Sherman, M., Nass, R., & Shapiro, T. (1984). Regional cerebral blood flow in autism. Journal of Autism and Developmental Disorders, 14, 436-439.
27.
Shih, T., Khachaturian, Z. S., Barry, H., III, & Hanin, J. (1976). Cholinergic mediation of the inhibitory effect of methylphenidate on nueronal activity in the reticular formation. Neuropharmacology, 15, 55-60.
28.
Spencer, T., Beiderman, J., Wilens, T., Harding, M., O’Donnell, D., & Griffin, S. (1996). Pharmacotherapy of attention deficit disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 409-432.
29.
Spencer, T., Wilens, T., Biederman, J., Faraone, S. V., Ablon, J. S., & Lapey, K. (1995). A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Archives of General Psychiatry, 52, 44-443.
30.
Spowart-Manning, L., & van der Staay, F. J. (2004). The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behavioral Brain Research, 151(1-2), 37-46.
31.
Tanguay, P. E. (2000). Peravasive developmental disorder: A 10-year review. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 1079-1095.
32.
Tokita, K., Yamazaki, M., Matsuoka, N., & Mutoh, S. (2002). Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacology Biochemistry Behavior, 73(3), 511-519.
33.
Tsukada, H., Nishiyama, S., Fukumoto, D., Ohba, H., & Kakiuchi, T. (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse, 52(1), 1-10.
34.
Volkmar, F., & Lord, C. (1999). Autism and pervasive developmental disorders. Cambridge, UK: Cambridge University Press.
35.
Wesnes, K., & Warburton, D. (1983). Smoking, nicotine, and human performance. Pharmacological Therapies, 21, 189-208.
36.
Wesnes, K., & Warburton, D. (1984). The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology, 82, 338-342.
37.
Westfall, T., Naes, L., & Paul, C. (1983). Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. General Pharmacology, 14, 321-325.
38.
Whitehead, A., Perdomo, C., Pratt, R. D., Birks, J., Wilcock, G. K., & Evans, J. G. (2004). Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: A meta-analysis of individual patient data from randomized controlled trials. International Journal of Geriatric Psychiatry, 19(7), 624-633.
39.
Wilens, T. E., Biederman, J., Giest, D. E., Steingard, R., & Spencer, T. (1993). Nortriptyline in the treatment of ADHD: A chart review of 58 cases. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 343-349.
40.
Wilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monteaux, M. C., et al. (1999). A pilot controlled clinical trial of ABT418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. American Journal of Psychiatry, 156, 1931-1937.
41.
Wilens, T. E., Biederman, J., Wong, J., Spencer, T. J., & Prince, J. B. (2000). Adjunctive donepezil in attention deficit hyperactivity disorder youth: Case series. Journal of Child and Adolescent Psychopharmacology, 10, 217-222.
42.
Zilbovicius, M., Garreau, B., Samson, Y., Remy, P., Barthelemy, C., Syrota, A., et al. (1995). Delayed maturation of the frontal cortex in childhood autism. American Journal of Psychiatry, 152, 248-252.
